← Back to headlines
Uncertainty Over Availability of 10 Innovative Oncology Drugs in Serbia
A contract for 10 innovative oncology drugs was signed in April between Serbia's RFZO and AstraZeneca, but the exact start date for their implementation for patients remains unknown.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.


